Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery

Journal of Medicinal Chemistry

Volumn 60, Issue 13, 2017, Pages 5235-5266

  Proschak, Ewgenij ^a   Heitel, Pascal ^a   Kalinowsky, Lena ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BIOMIMETIC MATERIAL; CARBOXYLIC ACID; CYTOCHROME P450; FARNESOID X RECEPTOR; FATTY ACID; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE RECEPTOR; LIPOXYGENASE; MONTELUKAST; ORGANIC ANION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRANLUKAST; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; ZAFIRLUKAST; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; BIOMIMETICS; CHEMICAL BINDING; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; INTESTINE ABSORPTION; MOLECULAR RECOGNITION; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; INFLAMMATION; METABOLISM; MOLECULAR MODEL;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DRUG DISCOVERY; FATTY ACIDS; HUMANS; INFLAMMATION; MODELS, MOLECULAR;

EID: 85024491935     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01287     Document Type: Review

References (243)

1. Aranda, A.; Pascual, A. Nuclear Hormone Receptors and Gene Expression Physiol. Rev. 2001, 81 (3) 1269-1304
2. Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N. A.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors Pharmacol. Rev. 2006, 58 (4) 726-741 10.1124/pr.58.4.5
3. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in Health and Disease Nature 2000, 405 (6785) 421-424 10.1038/35013000
4. Lamers, C.; Schubert-Zsilavecz, M.; Merk, D. Therapeutic Modulators of Peroxisome Proliferator-Activated Receptors (PPAR): A Patent Review (2008-present) Expert Opin. Ther. Pat. 2012, 22 (7) 803-841 10.1517/13543776.2012.699042
5. Merk, D.; Lamers, C.; Weber, J.; Flesch, D.; Gabler, M.; Proschak, E.; Schubert-Zsilavecz, M. Anthranilic Acid Derivatives as Nuclear Receptor modulators-Development of Novel PPAR Selective and Dual PPAR/FXR Ligands Bioorg. Med. Chem. 2015, 23 (3) 499-514 10.1016/j.bmc.2014.12.013
6. Ratziu, V.; Harrison, S. A.; Francque, S.; Bedossa, P.; Lehert, P.; Serfaty, L.; Romero-Gomez, M.; Boursier, J.; Abdelmalek, M.; Caldwell, S.; Drenth, J.; Anstee, Q. M.; Hum, D.; Hanf, R.; Roudot, A.; Megnien, S.; Staels, B.; Sanyal, A.; Mathurin, P.; Gournay, J.; Nguyen-Khac, E.; De Ledinghen, V.; Larrey, D.; Tran, A.; Bourliere, M.; Maynard-Muet, M.; Asselah, T.; Henrion, J.; Nevens, F.; Cassiman, D.; Geerts, A.; Moreno, C.; Beuers, U. H.; Galle, P. R.; Spengler, U.; Bugianesi, E.; Craxi, A.; Angelico, M.; Fargion, S.; Voiculescu, M.; Gheorghe, L.; Preotescu, L.; Caballeria, J.; Andrade, R. J.; Crespo, J.; Callera, J. L.; Ala, A.; Aithal, G.; Abouda, G.; Luketic, V.; Huang, M. A.; Gordon, S.; Pockros, P.; Poordad, F.; Shores, N.; Moehlen, M. W.; Bambha, K.; Clark, V.; Satapathy, S.; Parekh, S.; Reddy, R. K.; Sheikh, M. Y.; Szabo, G.; Vierling, J.; Foster, T.; Umpierrez, G.; Chang, C.; Box, T.; Gallegos-Orozco, J. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and-δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Gastroenterology 2016, 150 (5) 1147-1159 10.1053/j.gastro.2016.01.038
7. Hanke, T.; Merk, D.; Steinhilber, D.; Geisslinger, G.; Schubert-Zsilavecz, M. Small Molecules with Anti-Inflammatory Properties in Clinical Development Pharmacol. Ther. 2016, 157, 163-187 10.1016/j.pharmthera.2015.11.011
8. Pollock, C. B.; Rodriguez, O.; Martin, P. L.; Albanese, C.; Li, X.; Kopelovich, L.; Glazer, R. I. Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation PPAR Res. 2010, 2010, 571783 10.1155/2010/571783
9. Altucci, L.; Leibowitz, M.; Ogilvie, K.; de Lera, A.; Gronemeyer, H. RAR and RXR Modulation in Cancer and Metabolic Disease Nat. Rev. Drug Discovery 2007, 6 (10) 793-810 10.1038/nrd2397
10. Dawson, M.; Xia, Z. The Retinoid X Receptors and Their Ligands Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2012, 1821 (1) 21-56 10.1016/j.bbalip.2011.09.014
11. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X Receptors Pharmacol. Rev. 2006, 58 (4) 760-772 10.1124/pr.58.4.7
12. de Lera, á. R.; Krezel, W.; Rühl, R. An Endogenous Mammalian Retinoid X Receptor Ligand, At Last! ChemMedChem 2016, 11 (10) 1027-1037 10.1002/cmdc.201600105
13. Koster, K. P.; Smith, C.; Valencia-Olvera, A. C.; Thatcher, G. R. J.; Tai, L. M.; LaDu, M. J. Rexinoids as Therapeutics for Alzheimer Disease: Role of APOE Curr. Top. Med. Chem. 2017, 17 (6) 708-720 10.2174/1568026616666160617090227
14. Liby, K.; Sporn, M. Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges Curr. Top. Med. Chem. 2017, 17 (6) 721-730 10.2174/1568026616666160617090702
15. de Lera, A.; Bourguet, W.; Altucci, L.; Gronemeyer, H. Design of Selective Nuclear Receptor Modulators: RAR and RXR as a Case Study Nat. Rev. Drug Discovery 2007, 6 (10) 811-820 10.1038/nrd2398
16. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LX. Retinoic Acid Receptors Pharmacol. Rev. 2006, 58 (4) 712-725 10.1124/pr.58.4.4
17. Larange, A.; Cheroutre, H. Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System Annu. Rev. Immunol. 2016, 34 (1) 369-394 10.1146/annurev-immunol-041015-055427
18. Kuipers, F.; Bloks, V. W.; Groen, A. K. Beyond Intestinal Soap-Bile Acids in Metabolic Control Nat. Rev. Endocrinol. 2014, 10 (8) 488-498 10.1038/nrendo.2014.60
19. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal Chemistry of Farnesoid X Receptor Ligands: From Agonists and Antagonists to Modulators Future Med. Chem. 2012, 4 (8) 1015-1036 10.4155/fmc.12.47
20. Xu, Y. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases J. Med. Chem. 2016, 59 (14) 6553-6579 10.1021/acs.jmedchem.5b00342
21. Zhao, A.; Yu, J.; Lew, J.-L.; Huang, L.; Wright, S. D.; Cui, J. Polyunsaturated Fatty Acids Are FXR Ligands and Differentially Regulate Expression of FXR Targets DNA Cell Biol. 2004, 23 (8) 519-526 10.1089/1044549041562267
22. Arumugam, S.; Sreedhar, R.; Thandavarayan, R. A.; Karuppagounder, V.; Watanabe, K. Targeting Fatty Acid Metabolism in Heart Failure: Is It a Suitable Therapeutic Approach? Drug Discovery Today 2016, 21 (6) 1003-1008 10.1016/j.drudis.2016.02.010
23. Uto, Y. Recent Progress in the Discovery and Development of Stearoyl CoA Desaturase Inhibitors Chem. Phys. Lipids 2016, 197, 3-12 10.1016/j.chemphyslip.2015.08.018
24. Calderon-Dominguez, M.; Mir, J. F.; Fucho, R.; Weber, M.; Serra, D.; Herrero, L. Fatty Acid Metabolism and the Basis of Brown Adipose Tissue Function Adipocyte 2016, 5 (2) 98-118 10.1080/21623945.2015.1122857
25. Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D. Rationally Designed Multitarget Agents against Inflammation and Pain Curr. Med. Chem. 2013, 20 (13) 1783-1799 10.2174/0929867311320130013
26. Meirer, K.; Steinhilber, D.; Proschak, E. Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways Basic Clin. Pharmacol. Toxicol. 2014, 114 (1) 83-91 10.1111/bcpt.12134
27. Koeberle, A.; Laufer, S. A.; Werz, O. Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions J. Med. Chem. 2016, 59 (13) 5970-5986 10.1021/acs.jmedchem.5b01750
28. Jakobsson, P. J.; Morgenstern, R.; Mancini, J.; Ford-Hutchinson, A.; Persson, B. Common Structural Features of MAPEG - a Widespread Superfamily of Membrane Associated Proteins with Highly Divergent Functions in Eicosanoid and Glutathione Metabolism Protein Sci. 1999, 8 (3) 689-692 10.1110/ps.8.3.689
29. Smith, W. L.; Urade, Y.; Jakobsson, P.-J. Enzymes of the Cyclooxygenase Pathways of Prostanoid Biosynthesis Chem. Rev. 2011, 111 (10) 5821-5865 10.1021/cr2002992
30. Leclerc, P.; Idborg, H.; Spahiu, L.; Larsson, C.; Nekhotiaeva, N.; Wannberg, J.; Stenberg, P.; Korotkova, M.; Jakobsson, P.-J. Characterization of a Human and Murine mPGES-1 Inhibitor and Comparison to mPGES-1 Genetic Deletion in Mouse Models of Inflammation Prostaglandins Other Lipid Mediators 2013, 107, 26-34 10.1016/j.prostaglandins.2013.09.001
31. Chandrasekharan, J. A.; Sharma-Walia, N. Lipoxins: Nature's Way to Resolve Inflammation J. Inflammation Res. 2015, 8, 181-192 10.2147/JIR.S90380
32. Murphy, R. C.; Gijón, M. A. Biosynthesis and Metabolism of Leukotrienes Biochem. J. 2007, 405 (3) 379-395 10.1042/BJ20070289
33. Steinhilber, D.; Hofmann, B. Recent Advances in the Search for Novel 5-Lipoxygenase Inhibitors Basic Clin. Pharmacol. Toxicol. 2014, 114 (1) 70-77 10.1111/bcpt.12114
34. Powell, W. S.; Rokach, J. Biosynthesis, Biological Effects, and Receptors of Hydroxyeicosatetraenoic Acids (HETEs) and Oxoeicosatetraenoic Acids (Oxo-ETEs) Derived from Arachidonic Acid Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2015, 1851 (4) 340-355 10.1016/j.bbalip.2014.10.008
35. Guo, Y.; Zhang, W.; Giroux, C.; Cai, Y.; Ekambaram, P.; Dilly, A. K.; Hsu, A.; Zhou, S.; Maddipati, K. R.; Liu, J.; Joshi, S.; Tucker, S. C.; Lee, M. J.; Honn, K. V. Identification of the Orphan G Protein-Coupled Receptor GPR31 as a Receptor for 12-(S)-Hydroxyeicosatetraenoic Acid J. Biol. Chem. 2011, 286 (39) 33832-33840 10.1074/jbc.M110.216564
36. Serhan, C. N.; Petasis, N. A.; Resolvins and Protectins in Inflammation Resolution Chem. Rev. 2011, 111 (10) 5922-5943 10.1021/cr100396c
37. Serhan, C. N.; Chiang, N.; Dalli, J.; Levy, B. D. Lipid Mediators in the Resolution of Inflammation Cold Spring Harbor Perspect. Biol. 2015, 7 (2) a016311 10.1101/cshperspect.a016311
38. Imig, J. D. Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function Adv. Pharmacol. 2016, 77, 105-141 10.1016/bs.apha.2016.04.003
39. Lazaar, A. L.; Yang, L.; Boardley, R. L.; Goyal, N. S.; Robertson, J.; Baldwin, S. J.; Newby, D. E.; Wilkinson, I. B.; Tal-Singer, R.; Mayer, R. J.; Cheriyan, J. Pharmacokinetics, Pharmacodynamics and Adverse Event Profile of GSK2256294, a Novel Soluble Epoxide Hydrolase Inhibitor Br. J. Clin. Pharmacol. 2016, 81 (5) 971-979 10.1111/bcp.12855
40. Anandan, S.-K.; Webb, H. K.; Chen, D.; Wang, Y.-X.; Aavula, B. R.; Cases, S.; Cheng, Y.; Do, Z. N.; Mehra, U.; Tran, V.; Vincelette, J.; Waszczuk, J.; White, K.; Wong, K. R.; Zhang, L.-N.; Jones, P. D.; Hammock, B. D.; Patel, D. V.; Whitcomb, R.; MacIntyre, D. E.; Sabry, J.; Gless, R. 1-(1-Acetyl-Piperidin-4-Yl)-3-Adamantan-1-Yl-Urea (AR9281) as a Potent, Selective, and Orally Available Soluble Epoxide Hydrolase Inhibitor with Efficacy in Rodent Models of Hypertension and Dysglycemia Bioorg. Med. Chem. Lett. 2011, 21 (3) 983-988 10.1016/j.bmcl.2010.12.042
41. Miyamoto, J.; Hasegawa, S.; Kasubuchi, M.; Ichimura, A.; Nakajima, A.; Kimura, I. Nutritional Signaling via Free Fatty Acid Receptors Int. J. Mol. Sci. 2016, 17 (4) 450 10.3390/ijms17040450
42. Yonezawa, T.; Kurata, R.; Yoshida, K.; Murayama, M. A.; Cui, X.; Hasegawa, A. Free Fatty Acids-Sensing G Protein-Coupled Receptors in Drug Targeting and Therapeutics Curr. Med. Chem. 2013, 20 (31) 3855-3871 10.2174/09298673113209990168
43. Lamers, C.; Flesch, D.; Schubert-Zsilavecz, M.; Merk, D. Novel Prostaglandin Receptor Modulators: A Patent Review (2002-2012)-Part I: Non-EP Receptor Modulators Expert Opin. Ther. Pat. 2013, 23 (1) 47-77 10.1517/13543776.2013.736495
44. Flesch, D.; Merk, D.; Lamers, C.; Schubert-Zsilavecz, M. Novel Prostaglandin Receptor Modulators - Part II: EP Receptor Modulators; a Patent Review (2002-2012) Expert Opin. Ther. Pat. 2013, 23 (2) 233-267 10.1517/13543776.2013.744822
45. Woodward, D. F.; Jones, R. L.; Narumiya, S. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress Pharmacol. Rev. 2011, 63 (3) 471-538 10.1124/pr.110.003517
46. Bäck, M.; Powell, W. S.; Dahlén, S.-E.; Drazen, J. M.; Evans, J. F.; Serhan, C. N.; Shimizu, T.; Yokomizo, T.; Rovati, G. E. Update on Leukotriene, Lipoxin and Oxoeicosanoid Receptors: IUPHAR Review 7 Br. J. Pharmacol. 2014, 171 (15) 3551-3574 10.1111/bph.12665
47. Bäck, M.; Dahlén, S.-E.; Drazen, J. M.; Evans, J. F.; Serhan, C. N.; Shimizu, T.; Yokomizo, T.; Rovati, G. E. International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions Pharmacol. Rev. 2011, 63 (3) 539-584 10.1124/pr.110.004184
48. Chiang, N.; Serhan, C. N.; Dahlén, S.-E.; Drazen, J. M.; Hay, D. W. P.; Rovati, G. E.; Shimizu, T.; Yokomizo, T.; Brink, C. The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo Pharmacol. Rev. 2006, 58 (3) 463-487 10.1124/pr.58.3.4
49. Romano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and Aspirin-Triggered Lipoxins in Resolution of Inflammation Eur. J. Pharmacol. 2015, 760, 49-63 10.1016/j.ejphar.2015.03.083
50. Stalder, A. K.; Lott, D.; Strasser, D.; Cruz, H.; Krause, A.; Groenen, P.; Dingemanse, J. Biomarker-Guided Clinical Development of the First-in-Class Anti- Inflammatory FPR2/ALX Agonist ACT-389949 Br. J. Clin. Pharmacol. 2017, 83 (3) 476-486 10.1111/bcp.13149
51. Im, D.-S. Omega-3 Fatty Acids in Anti-Inflammation (pro-Resolution) and GPCRs Prog. Lipid Res. 2012, 51 (3) 232-237 10.1016/j.plipres.2012.02.003
52. Krishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.-H.; Yang, R.; Petasis, N. A.; Serhan, C. N. Resolvin D1 Binds Human Phagocytes with Evidence for Proresolving Receptors Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (4) 1660-1665 10.1073/pnas.0907342107
53. Arita, M.; Ohira, T.; Sun, Y.-P.; Elangovan, S.; Chiang, N.; Serhan, C. N. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation J. Immunol. 2007, 178 (6) 3912-3917 10.4049/jimmunol.178.6.3912
54. Cash, J. L.; Hart, R.; Russ, A.; Dixon, J. P. C.; Colledge, W. H.; Doran, J.; Hendrick, A. G.; Carlton, M. B. L.; Greaves, D. R. Synthetic Chemerin-Derived Peptides Suppress Inflammation through ChemR23 J. Exp. Med. 2008, 205 (4) 767-775 10.1084/jem.20071601
55. Mariani, F.; Roncucci, L. Chemerin/chemR23 Axis in Inflammation Onset and Resolution Inflammation Res. 2015, 64 (2) 85-95 10.1007/s00011-014-0792-7
56. Furuhashi, M.; Hotamisligil, G. S. Fatty Acid-Binding Proteins: Role in Metabolic Diseases and Potential as Drug Targets Nat. Rev. Drug Discovery 2008, 7 (6) 489-503 10.1038/nrd2589
57. Wolfrum, C.; Borrmann, C. M.; Borchers, T.; Spener, F. Fatty Acids and Hypolipidemic Drugs Regulate Peroxisome Proliferator-Activated Receptors Alpha-and Gamma-Mediated Gene Expression via Liver Fatty Acid Binding Protein: A Signaling Path to the Nucleus Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (5) 2323-2328 10.1073/pnas.051619898
58. Zimmer, J. S. D.; Dyckes, D. F.; Bernlohr, D. A.; Murphy, R. C. Fatty Acid Binding Proteins Stabilize Leukotriene A4: Competition with Arachidonic Acid but Not Other Lipoxygenase Products J. Lipid Res. 2004, 45 (11) 2138-2144 10.1194/jlr.M400240-JLR200
59. Velkov, T.; Chuang, S.; Wielens, J.; Sakellaris, H.; Charman, W. N.; Porter, C. J. H.; Scanlon, M. J. The Interaction of Lipophilic Drugs with Intestinal Fatty Acid-Binding Protein J. Biol. Chem. 2005, 280 (18) 17769-17776 10.1074/jbc.M410193200
60. Furuhashi, M.; Tuncman, G.; Görgün, C. Z.; Makowski, L.; Atsumi, G.; Vaillancourt, E.; Kono, K.; Babaev, V. R.; Fazio, S.; Linton, M. F.; Sulsky, R.; Robl, J. A.; Parker, R. A.; Hotamisligil, G. S. Treatment of Diabetes and Atherosclerosis by Inhibiting Fatty-Acid-Binding Protein aP2 Nature 2007, 447 (7147) 959-965 10.1038/nature05844
61. Harjes, U.; Bridges, E.; Gharpure, K. M.; Roxanis, I.; Sheldon, H.; Miranda, F.; Mangala, L. S.; Pradeep, S.; Lopez-Berestein, G.; Ahmed, A.; Fielding, B.; Sood, A. K.; Harris, A. L. Antiangiogenic and Tumour Inhibitory Effects of Downregulating Tumour Endothelial FABP4 Oncogene 2017, 36, 912-921 10.1038/onc.2016.256
62. Liang, J.; Edelsbrunner, H.; Woodward, C. Anatomy of Protein Pockets and Cavities: Measurement of Binding Site Geometry and Implications for Ligand Design Protein Sci. 1998, 7 (9) 1884-1897 10.1002/pro.5560070905
63. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery Nucleic Acids Res. 2012, 40 (Database issue) D1100-D1107 10.1093/nar/gkr777
64. Ladbury, J. E.; Klebe, G.; Freire, E. Adding Calorimetric Data to Decision Making in Lead Discovery: A Hot Tip Nat. Rev. Drug Discovery 2010, 9 (1) 23-27 10.1038/nrd3054
65. Wittmann, S. K.; Kalinowsky, L.; Kramer, J. S.; Bloecher, R.; Knapp, S.; Steinhilber, D.; Pogoryelov, D.; Proschak, E.; Heering, J. Thermodynamic Properties of Leukotriene A4 Hydrolase Inhibitors Bioorg. Med. Chem. 2016, 24 (21) 5243-5248 10.1016/j.bmc.2016.08.047
66. Snelgrove, R. J.; Jackson, P. L.; Hardison, M. T.; Noerager, B. D.; Kinloch, A.; Gaggar, A.; Shastry, S.; Rowe, S. M.; Shim, Y. M.; Hussell, T.; Blalock, J. E. A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation Science 2010, 330 (6000) 90-94 10.1126/science.1190594
67. Stsiapanava, A.; Olsson, U.; Wan, M.; Kleinschmidt, T.; Rutishauser, D.; Zubarev, R. A.; Samuelsson, B.; Rinaldo-Matthis, A.; Haeggström, J. Z. Binding of Pro-Gly-Pro at the Active Site of Leukotriene A4 Hydrolase/aminopeptidase and Development of an Epoxide Hydrolase Selective Inhibitor Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (11) 4227-4232 10.1073/pnas.1402136111
68. Velkov, T.; Horne, J.; Laguerre, A.; Jones, E.; Scanlon, M. J.; Porter, C. J. H. Examination of the Role of Intestinal Fatty Acid-Binding Protein in Drug Absorption Using a Parallel Artificial Membrane Permeability Assay Chem. Biol. 2007, 14 (4) 453-465 10.1016/j.chembiol.2007.03.009
69. Velkov, T. Thermodynamics of Lipophilic Drug Binding to Intestinal Fatty Acid Binding Protein and Permeation across Membranes Mol. Pharmaceutics 2009, 6 (2) 557-570 10.1021/mp800227w
70. Stumpe, M. C.; Blinov, N.; Wishart, D.; Kovalenko, A.; Pande, V. S. Calculation of Local Water Densities in Biological Systems: A Comparison of Molecular Dynamics Simulations and the 3D-RISM-KH Molecular Theory of Solvation J. Phys. Chem. B 2011, 115 (2) 319-328 10.1021/jp102587q
71. Sacchettini, J. C.; Gordon, J. I.; Banaszak, L. J. Refined Apoprotein Structure of Rat Intestinal Fatty Acid Binding Protein Produced in Escherichia Coli Proc. Natl. Acad. Sci. U. S. A. 1989, 86 (20) 7736-7740 10.1073/pnas.86.20.7736
72. Sacchettini, J. C.; Gordon, J. I.; Banaszak, L. J. Crystal Structure of Rat Intestinal Fatty-Acid-Binding Protein. Refinement and Analysis of the Escherichia Coli-Derived Protein with Bound Palmitate J. Mol. Biol. 1989, 208 (2) 327-339 10.1016/0022-2836(89)90392-6
73. Laghezza, A.; Pochetti, G.; Lavecchia, A.; Fracchiolla, G.; Faliti, S.; Piemontese, L.; Di Giovanni, C.; Iacobazzi, V.; Infantino, V.; Montanari, R.; Capelli, D.; Tortorella, P.; Loiodice, F. New 2-(Aryloxy)-3-Phenylpropanoic Acids as Peroxisome Proliferator-Activated Receptor A/γ Dual Agonists Able to Upregulate Mitochondrial Carnitine Shuttle System Gene Expression J. Med. Chem. 2013, 56 (1) 60-72 10.1021/jm301018z
74. Porcelli, L.; Gilardi, F.; Laghezza, A.; Piemontese, L.; Mitro, N.; Azzariti, A.; Altieri, F.; Cervoni, L.; Fracchiolla, G.; Giudici, M.; Guerrini, U.; Lavecchia, A.; Montanari, R.; Di Giovanni, C.; Paradiso, A.; Pochetti, G.; Simone, G. M.; Tortorella, P.; Crestani, M.; Loiodice, F. Synthesis, Characterization and Biological Evaluation of Ureidofibrate-like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity J. Med. Chem. 2012, 55 (1) 37-54 10.1021/jm201306q
75. Ramarao, M. K.; Shen, M. W. H.; Murphy, E. A.; Duan, W.; Zhao, Y.; McKew, J.; Lee, K. L.; Thakker, P.; Behnke, M. L.; Clark, J. D. Thermodynamic Characterization of Cytosolic Phospholipase A2 Alpha Inhibitors Anal. Biochem. 2008, 383 (2) 217-225 10.1016/j.ab.2008.08.025
76. Yang, H. J.; Youn, H.; Seong, K. M.; Yun, Y. J.; Kim, W.; Kim, Y. H.; Lee, J. Y.; Kim, C. S.; Jin, Y.-W.; Youn, B. Psoralidin, a Dual Inhibitor of COX-2 and 5-LOX, Regulates Ionizing Radiation (IR)-Induced Pulmonary Inflammation Biochem. Pharmacol. 2011, 82 (5) 524-534 10.1016/j.bcp.2011.05.027
77. Bissantz, C.; Kuhn, B.; Stahl, M. A Medicinal Chemist's Guide to Molecular Interactions J. Med. Chem. 2010, 53 (14) 5061-5084 10.1021/jm100112j
78. Freire, E. Do Enthalpy and Entropy Distinguish First in Class from Best in Class? Drug Discovery Today 2008, 13 (19-20) 869-874 10.1016/j.drudis.2008.07.005
79. Tarcsay, á.; Keseru, G. M. Is There a Link between Selectivity and Binding Thermodynamics Profiles? Drug Discovery Today 2015, 20 (1) 86-94 10.1016/j.drudis.2014.09.014
80. Bleicher, K. H.; Böhm, H.-J.; Müller, K.; Alanine, A. I. Hit and Lead Generation: Beyond High-Throughput Screening Nat. Rev. Drug Discovery 2003, 2 (5) 369-378 10.1038/nrd1086
81. Robert, A.; Nezamis, J. E.; Phillips, J. P. Inhibition of Gastric Secretion by Prostaglandins Am. J. Dig. Dis. 1967, 12 (10) 1073-1076 10.1007/BF02233268
82. Collins, P. W.; Gasiecki, A. F.; Jones, P. H.; Bauer, R. F.; Gullikson, G. W.; Woods, E. M.; Bianchi, R. G. Synthesis and Gastric Antisecretory Properties of Alpha Chain Diene Derivatives of Misoprostol J. Med. Chem. 1986, 29 (7) 1195-1201 10.1021/jm00157a013
83. Barreiro, E. J.; Kümmerle, A. E.; Fraga, C. A. M. The Methylation Effect in Medicinal Chemistry Chem. Rev. 2011, 111 (9) 5215-5246 10.1021/cr200060g
84. Johansson, C.; Kollberg, B. Stimulation by Intragastrically Administered E2 Prostaglandins of Human Gastric Mucus Output Eur. J. Clin. Invest. 1979, 9 (3) 229-232 10.1111/j.1365-2362.1979.tb00928.x
85. Karim, S. M.; Fung, W. P. Effects of Some Naturally Occurring Prostaglandins and Synthetic Analogues on Gastric Secretion and Ulcer Healing in Man Adv. Prostaglandin Thromboxane Res. 1976, 2, 529-539
86. Floyd, M. B.; Schaub, R. E.; Weiss, M. J. Prostaglandins and Congeners. IX. The Synthesis of 15-Deoxy-16-, 17-, or 20-Hydroxyprostaglandins and 15-Deoxy-15-Hydroxymethylprostaglandin E2 Prostaglandins 1975, 10 (2) 289-296 10.1016/0090-6980(75)90047-7
87. Patel, S. S.; Spencer, C. M.; Latanoprost, A. Review of Its Pharmacological Properties, Clinical Efficacy and Tolerability in the Management of Primary Open-Angle Glaucoma and Ocular Hypertension Drugs Aging 1996, 9 (5) 363-378 10.2165/00002512-199609050-00007
88. Duvvuri, S.; Majumdar, S.; Mitra, A. K. Drug Delivery to the Retina: Challenges and Opportunities Expert Opin. Biol. Ther. 2003, 3 (1) 45-56 10.1517/14712598.3.1.45
89. Resul, B.; Stjernschantz, J.; No, K.; Liljebris, C.; Selén, G.; Astin, M.; Karlsson, M.; Bito, L. Z. Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents J. Med. Chem. 1993, 36 (2) 243-248 10.1021/jm00054a008
90. Duvvuri, S.; Majumdar, S.; Mitra, A. K. Role of Metabolism in Ocular Drug Delivery Curr. Drug Metab. 2004, 5 (6) 507-515 10.2174/1389200043335342
91. Huttunen, K. M.; Raunio, H.; Rautio, J. Prodrugs - from Serendipity to Rational Design Pharmacol. Rev. 2011, 63 (3) 750-771 10.1124/pr.110.003459
92. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity J. Med. Chem. 2002, 45 (17) 3569-3572 10.1021/jm025529g
93. Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V. S.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Impact of High-Throughput Screening in Biomedical Research Nat. Rev. Drug Discovery 2011, 10 (3) 188-195 10.1038/nrd3368
94. Ishikawa, T.; Takano, K.; Yasufuku-Takano, J.; Fujita, T.; Igarashi, T.; Miura, M.; Hata, K. Estrogenic Impurities in Labware Nat. Biotechnol. 2001, 19 (9) 812 10.1038/nbt0901-812
95. Olivieri, A.; Degenhardt, O. S.; McDonald, G. R.; Narang, D.; Paulsen, I. M.; Kozuska, J. L.; Holt, A. On the Disruption of Biochemical and Biological Assays by Chemicals Leaching from Disposable Laboratory Plasticware Can. J. Physiol. Pharmacol. 2012, 90 (6) 697-703 10.1139/y2012-049
96. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-Throughput Assays for Promiscuous Inhibitors Nat. Chem. Biol. 2005, 1 (3) 146-148 10.1038/nchembio718
97. Wiegard, A.; Hanekamp, W.; Griessbach, K.; Fabian, J.; Lehr, M. Pyrrole Alkanoic Acid Derivatives as Nuisance Inhibitors of Microsomal Prostaglandin E2 Synthase-1 Eur. J. Med. Chem. 2012, 48, 153-163 10.1016/j.ejmech.2011.12.009
98. Feng, B. Y.; Shoichet, B. K. A Detergent-Based Assay for the Detection of Promiscuous Inhibitors Nat. Protoc. 2006, 1 (2) 550-553 10.1038/nprot.2006.77
99. Bajorath, J. Integration of Virtual and High-Throughput Screening Nat. Rev. Drug Discovery 2002, 1 (11) 882-894 10.1038/nrd941
100. Tanrikulu, Y.; Krüger, B.; Proschak, E. The Holistic Integration of Virtual Screening in Drug Discovery Drug Discovery Today 2013, 18 (7-8) 358-364 10.1016/j.drudis.2013.01.007
101. Lewis, S. N.; Bassaganya-Riera, J.; Bevan, D. R. Virtual Screening as a Technique for PPAR Modulator Discovery PPAR Res. 2010, 2010, 861238 10.1155/2010/861238
102. Markt, P.; Petersen, R. K.; Flindt, E. N.; Kristiansen, K.; Kirchmair, J.; Spitzer, G.; Distinto, S.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. Discovery of Novel PPAR Ligands by a Virtual Screening Approach Based on Pharmacophore Modeling, 3D Shape, and Electrostatic Similarity Screening J. Med. Chem. 2008, 51 (20) 6303-6317 10.1021/jm800128k
103. Proschak, E.; Zettl, H.; Tanrikulu, Y.; Weisel, M.; Kriegl, J. M.; Rau, O.; Schubert-Zsilavecz, M.; Schneider, G. From Molecular Shape to Potent Bioactive Agents I: Bioisosteric Replacement of Molecular Fragments ChemMedChem 2009, 4 (1) 41-44 10.1002/cmdc.200800313
104. Derksen, S.; Rau, O.; Schneider, P.; Schubert-Zsilavecz, M.; Schneider, G. Virtual Screening for PPAR Modulators Using a Probabilistic Neural Network ChemMedChem 2006, 1 (12) 1346-1350 10.1002/cmdc.200600166
105. Salam, N. K.; Huang, T. H.-W.; Kota, B. P.; Kim, M. S.; Li, Y.; Hibbs, D. E. Novel PPAR-Gamma Agonists Identified from a Natural Product Library: A Virtual Screening, Induced-Fit Docking and Biological Assay Study Chem. Biol. Drug Des. 2008, 71 (1) 57-70 10.1111/j.1747-0285.2007.00606.x
106. Lu, I.-L.; Huang, C.-F.; Peng, Y.-H.; Lin, Y.-T.; Hsieh, H.-P.; Chen, C.-T.; Lien, T.-W.; Lee, H.-J.; Mahindroo, N.; Prakash, E.; Yueh, A.; Chen, H.-Y.; Goparaju, C. M. V; Chen, X.; Liao, C.-C.; Chao, Y.-S.; Hsu, J. T.-A.; Wu, S.-Y. Structure-Based Drug Design of a Novel Family of PPARgamma Partial Agonists: Virtual Screening, X-Ray Crystallography, and in Vitro/in Vivo Biological Activities J. Med. Chem. 2006, 49 (9) 2703-2712 10.1021/jm051129s
107. Schuster, D.; Markt, P.; Grienke, U.; Mihaly-Bison, J.; Binder, M.; Noha, S. M.; Rollinger, J. M.; Stuppner, H.; Bochkov, V. N.; Wolber, G. Pharmacophore-Based Discovery of FXR Agonists. Part I: Model Development and Experimental Validation Bioorg. Med. Chem. 2011, 19 (23) 7168-7180 10.1016/j.bmc.2011.09.056
108. Proschak, E.; Rupp, M.; Derksen, S.; Schneider, G. Shapelets: Possibilities and Limitations of Shape-Based Virtual Screening J. Comput. Chem. 2008, 29 (1) 108-114 10.1002/jcc.20770
109. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A Fast Method of Molecular Shape Comparison: A Simple Application of a Gaussian Description of Molecular Shape J. Comput. Chem. 1996, 17 (14) 1653-1666 10.1002/(SICI)1096-987X(19961115)17:14<1653::AID-JCC7>3.0.CO;2-K
110. Kirchmair, J.; Distinto, S.; Markt, P.; Schuster, D.; Spitzer, G. M.; Liedl, K. R.; Wolber, G. How to Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information J. Chem. Inf. Model. 2009, 49 (3) 678-692 10.1021/ci8004226
111. Rörsch, F.; Wobst, I.; Zettl, H.; Schubert-Zsilavecz, M.; Grösch, S.; Geisslinger, G.; Schneider, G.; Proschak, E. Nonacidic Inhibitors of Human Microsomal Prostaglandin Synthase 1 (mPGES 1) Identified by a Multistep Virtual Screening Protocol J. Med. Chem. 2010, 53 (2) 911-915 10.1021/jm9012505
112. Hamza, A.; Zhao, X.; Tong, M.; Tai, H.-H.; Zhan, C.-G. Novel Human mPGES-1 Inhibitors Identified through Structure-Based Virtual Screening Bioorg. Med. Chem. 2011, 19 (20) 6077-6086 10.1016/j.bmc.2011.08.040
113. Hofmann, B.; Franke, L.; Proschak, E.; Tanrikulu, Y.; Schneider, P.; Steinhilber, D.; Schneider, G. Scaffold-Hopping Cascade Yields Potent Inhibitors of 5-Lipoxygenase ChemMedChem 2008, 3 (10) 1535-1538 10.1002/cmdc.200800153
114. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.; Yan, W.; Ma, R.; Zhu, J.; Shen, X.; Jiang, H.; Chen, L.; Li, J. Discovery and Optimization of 1,3,4-Trisubstituted-Pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists J. Med. Chem. 2012, 55 (16) 7037-7053 10.1021/jm3002718
115. Fu, J.; Si, P.; Zheng, M.; Chen, L.; Shen, X.; Tang, Y.; Li, W. Discovery of New Non-Steroidal FXR Ligands via a Virtual Screening Workflow Based on Phase Shape and Induced Fit Docking Bioorg. Med. Chem. Lett. 2012, 22 (22) 6848-6853 10.1016/j.bmcl.2012.09.045
116. Temml, V.; Voss, C. V.; Dirsch, V. M.; Schuster, D. Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening J. Chem. Inf. Model. 2014, 54 (2) 367-371 10.1021/ci400682b
117. Murray, C. W.; Rees, D. C. The Rise of Fragment-Based Drug Discovery Nat. Chem. 2009, 1 (3) 187-192 10.1038/nchem.217
118. Artis, D. R.; Lin, J. J.; Zhang, C.; Wang, W.; Mehra, U.; Perreault, M.; Erbe, D.; Krupka, H. I.; England, B. P.; Arnold, J.; Plotnikov, A. N.; Marimuthu, A.; Nguyen, H.; Will, S.; Signaevsky, M.; Kral, J.; Cantwell, J.; Settachatgull, C.; Yan, D. S.; Fong, D.; Oh, A.; Shi, S.; Womack, P.; Powell, B.; Habets, G.; West, B. L.; Zhang, K. Y. J.; Milburn, M. V.; Vlasuk, G. P.; Hirth, K. P.; Nolop, K.; Bollag, G.; Ibrahim, P. N.; Tobin, J. F. Scaffold-Based Discovery of Indeglitazar, a PPAR Pan-Active Anti-Diabetic Agent Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (1) 262-267 10.1073/pnas.0811325106
119. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "Rule of Three" for Fragment-Based Lead Discovery? Drug Discovery Today 2003, 8 (19) 876-877 10.1016/S1359-6446(03)02831-9
120. Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-Based Lead Discovery: Leads by Design Drug Discovery Today 2005, 10 (14) 987-992 10.1016/S1359-6446(05)03511-7
121. Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The "Rule of Three" for Fragment-Based Drug Discovery: Where Are We Now? Nat. Rev. Drug Discovery 2013, 12 (8) 644-645 10.1038/nrd3926-c1
122. Card, G. L.; Blasdel, L.; England, B. P.; Zhang, C.; Suzuki, Y.; Gillette, S.; Fong, D.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J. A Family of Phosphodiesterase Inhibitors Discovered by Cocrystallography and Scaffold-Based Drug Design Nat. Biotechnol. 2005, 23 (2) 201-207 10.1038/nbt1059
123. Davies, D. R.; Mamat, B.; Magnusson, O. T.; Christensen, J.; Haraldsson, M. H.; Mishra, R.; Pease, B.; Hansen, E.; Singh, J.; Zembower, D.; Kim, H.; Kiselyov, A. S.; Burgin, A. B.; Gurney, M. E.; Stewart, L. J. Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography J. Med. Chem. 2009, 52 (15) 4694-4715 10.1021/jm900259h
124. Amano, Y.; Yamaguchi, T.; Tanabe, E. Structural Insights into Binding of Inhibitors to Soluble Epoxide Hydrolase Gained by Fragment Screening and X-Ray Crystallography Bioorg. Med. Chem. 2014, 22 (8) 2427-2434 10.1016/j.bmc.2014.03.001
125. Amano, Y.; Tanabe, E.; Yamaguchi, T. Identification of N-Ethylmethylamine as a Novel Scaffold for Inhibitors of Soluble Epoxide Hydrolase by Crystallographic Fragment Screening Bioorg. Med. Chem. 2015, 23 (10) 2310-2317 10.1016/j.bmc.2015.03.083
126. Hohwy, M.; Spadola, L.; Lundquist, B.; Hawtin, P.; Dahmén, J.; Groth-Clausen, I.; Nilsson, E.; Persdotter, S.; von Wachenfeldt, K.; Folmer, R. H. A.; Edman, K. Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design J. Med. Chem. 2008, 51 (7) 2178-2186 10.1021/jm701509k
127. Lauro, G.; Tortorella, P.; Bertamino, A.; Ostacolo, C.; Koeberle, A.; Fischer, K.; Bruno, I.; Terracciano, S.; Gomez-Monterrey, I. M.; Tauro, M.; Loiodice, F.; Novellino, E.; Riccio, R.; Werz, O.; Campiglia, P.; Bifulco, G. Structure-Based Design of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors Using a Virtual Fragment Growing Optimization Scheme ChemMedChem 2016, 11 (6) 612-619 10.1002/cmdc.201500598
128. Lee, K.; Pham, V. C.; Choi, M. J.; Kim, K. J.; Lee, K.-T.; Han, S.-G.; Yu, Y. G.; Lee, J. Y. Fragment-Based Discovery of Novel and Selective mPGES-1 Inhibitors Part 1: Identification of Sulfonamido-1,2,3-Triazole-4,5-Dicarboxylic Acid Bioorg. Med. Chem. Lett. 2013, 23 (1) 75-80 10.1016/j.bmcl.2012.11.019
129. Proschak, E.; Sander, K.; Zettl, H.; Tanrikulu, Y.; Rau, O.; Schneider, P.; Schubert-Zsilavecz, M.; Stark, H.; Schneider, G. From Molecular Shape to Potent Bioactive Agents II: Fragment-Based de Novo Design ChemMedChem 2009, 4 (1) 45-48 10.1002/cmdc.200800314
130. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists J. Med. Chem. 1988, 31 (12) 2235-2246 10.1021/jm00120a002
131. Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. M. Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates Mini-Rev. Med. Chem. 2007, 7 (11) 1108-1119 10.2174/138955707782331722
132. Barelier, S.; Krimm, I. Ligand Specificity, Privileged Substructures and Protein Druggability from Fragment-Based Screening Curr. Opin. Chem. Biol. 2011, 15 (4) 469-474 10.1016/j.cbpa.2011.02.020
133. Mendgen, T.; Steuer, C.; Klein, C. D. Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry J. Med. Chem. 2012, 55 (2) 743-753 10.1021/jm201243p
134. DeSimone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W. Pippin, D. A. Privileged Structures: Applications in Drug Discovery Comb. Chem. High Throughput Screening 2004, 7 (5) 473-494 10.2174/1386207043328544
135. Hart, F. D.; Boardman, P. L. Indomethacin: A New Non-Steroid Anti-Inflammatory Agent Br. Med. J. 1963, 2 (5363) 965-970 10.1136/bmj.2.5363.965
136. Stock, N. S.; Bain, G.; Zunic, J.; Li, Y.; Ziff, J.; Roppe, J.; Santini, A.; Darlington, J.; Prodanovich, P.; King, C. D.; Baccei, C.; Lee, C.; Rong, H.; Chapman, C.; Broadhead, A.; Lorrain, D.; Correa, L.; Hutchinson, J. H.; Evans, J. F.; Prasit, P. 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of AM803, a Potent, Oral, Once Daily FLAP Inhibitor J. Med. Chem. 2011, 54 (23) 8013-8029 10.1021/jm2008369
137. Matassa, V. G.; Maduskuie, T. P.; Shapiro, H. S.; Hesp, B.; Snyder, D. W.; Aharony, D.; Krell, R. D.; Keith, R. A. Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/activity Relationships of 1,3,5-Substituted Indoles and Indazoles J. Med. Chem. 1990, 33 (6) 1781-1790 10.1021/jm00168a037
138. de Sá Alves, F. R.; Barreiro, E. J.; Fraga, C. A. M. From Nature to Drug Discovery: The Indole Scaffold as a "Privileged Structure Mini-Rev. Med. Chem. 2009, 9 (7) 782-793 10.2174/138955709788452649
139. Schnur, D. M.; Hermsmeier, M. A.; Tebben, A. J. Are Target-Family-Privileged Substructures Truly Privileged? J. Med. Chem. 2006, 49 (6) 2000-2009 10.1021/jm0502900
140. Lehmann, J. M.; Lenhard, J. M.; Oliver, B. B.; Ringold, G. M.; Kliewer, S. A. Peroxisome Proliferator-Activated Receptors Alpha and Gamma Are Activated by Indomethacin and Other Non-Steroidal Anti-Inflammatory Drugs J. Biol. Chem. 1997, 272 (6) 3406-3410 10.1074/jbc.272.6.3406
141. Hori, T.; Ishijima, J.; Yokomizo, T.; Ago, H.; Shimizu, T.; Miyano, M. Crystal Structure of Anti-Configuration of Indomethacin and Leukotriene B4 12-hydroxydehydrogenase/15-Oxo-Prostaglandin 13-Reductase Complex Reveals the Structural Basis of Broad Spectrum Indomethacin Efficacy J. Biochem. 2006, 140 (3) 457-466 10.1093/jb/mvj176
142. Kahnt, A. S.; Rörsch, F.; Diehl, O.; Hofmann, B.; Lehmann, C.; Steinbrink, S. D.; Angioni, C.; Geisslinger, G.; Grösch, S.; Steinhilber, D.; Maier, T. J. Cysteinyl Leukotriene-Receptor-1 Antagonists Interfere with PGE2 Synthesis by Inhibiting mPGES-1 Activity Biochem. Pharmacol. 2013, 86 (2) 286-296 10.1016/j.bcp.2013.05.005
143. Santilli, A. A.; Scotese, A. C.; Tomarelli, R. M. A Potent Antihypercholesterolemic Agent: [4-Chloro-6-(2,3-Xylidino)-2-Pyrimidinylthio]acetic Acid (Wy-14643) Experientia 1974, 30 (10) 1110-1111 10.1007/BF01923636
144. Merk, D.; Zettl, M.; Steinhilber, D.; Werz, O.; Schubert-Zsilavecz, M. Pirinixic Acids: Flexible Fatty Acid Mimetics with Various Biological Activities Future Med. Chem. 2015, 7 (12) 1597-1616 10.4155/fmc.15.87
145. Thieme, T. M.; Steri, R.; Proschak, E.; Paulke, A.; Schneider, G.; Schubert-Zsilavecz, M. Rational Design of a Pirinixic Acid Derivative That Acts as Subtype-Selective PPARgamma Modulator Bioorg. Med. Chem. Lett. 2010, 20 (8) 2469-2473 10.1016/j.bmcl.2010.03.008
146. Lamers, C.; Dittrich, M.; Steri, R.; Proschak, E.; Schubert-Zsilavecz, M. Molecular Determinants for Improved Activity at PPARα: Structure-Activity Relationship of Pirinixic Acid Derivatives, Docking Study and Site-Directed Mutagenesis of PPARα Bioorg. Med. Chem. Lett. 2014, 24 (16) 4048-4052 10.1016/j.bmcl.2014.05.058
147. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic Acid Derivatives as Novel Dual Inhibitors of Microsomal Prostaglandin E2 Synthase-1 and 5-Lipoxygenase J. Med. Chem. 2008, 51 (24) 8068-8076 10.1021/jm801085s
148. Hanke, T.; Dehm, F.; Liening, S.; Popella, S.-D.; Maczewsky, J.; Pillong, M.; Kunze, J.; Weinigel, C.; Barz, D.; Kaiser, A.; Wurglics, M.; Lämmerhofer, M.; Schneider, G.; Sautebin, L.; Schubert-Zsilavecz, M.; Werz, O. Aminothiazole-Featured Pirinixic Acid Derivatives as Dual 5-Lipoxygenase and Microsomal Prostaglandin E2 Synthase-1 Inhibitors with Improved Potency and Efficiency in Vivo J. Med. Chem. 2013, 56 (22) 9031-9044 10.1021/jm401557w
149. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged Molecules for Protein Binding Identified from NMR-Based Screening J. Med. Chem. 2000, 43 (18) 3443-3447 10.1021/jm000164q
150. Ballatore, C.; Huryn, D. M.; Smith, A. B. Carboxylic Acid (Bio)isosteres in Drug Design ChemMedChem 2013, 8 (3) 385-395 10.1002/cmdc.201200585
151. Pajouhesh, H.; Lenz, G. R. Medicinal Chemical Properties of Successful Central Nervous System Drugs NeuroRx 2005, 2 (4) 541-553 10.1602/neurorx.2.4.541
152. Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design J. Med. Chem. 2011, 54 (8) 2529-2591 10.1021/jm1013693
153. Lassalas, P.; Gay, B.; Lasfargeas, C.; James, M. J.; Tran, V.; Vijayendran, K. G.; Brunden, K. R.; Kozlowski, M. C.; Thomas, C. J.; Smith, A. B.; Huryn, D. M.; Ballatore, C. Structure Property Relationships of Carboxylic Acid Isosteres J. Med. Chem. 2016, 59 (7) 3183-3203 10.1021/acs.jmedchem.5b01963
154. Gervois, P.; Fruchart, J.-C.; Staels, B. Drug Insight: Mechanisms of Action and Therapeutic Applications for Agonists of Peroxisome Proliferator-Activated Receptors Nat. Clin. Pract. Endocrinol. Metab. 2007, 3 (2) 145-156 10.1038/ncpendmet0397
155. Aharony, D.; Falcone, R. C.; Yee, Y. K.; Hesp, B.; Giles, R. E.; Krell, R. D. Biochemical and Pharmacological Characterization of the Binding of the Selective Peptide-Leukotriene Antagonist, 3H-ICI 198,615, to Leukotriene D4 Receptors in Guinea-Pig Lung Membranes Ann. N. Y. Acad. Sci. 1988, 524, 162-180 10.1111/j.1749-6632.1988.tb38539.x
156. Bell, R. L.; Young, P. R.; Albert, D.; Lanni, C.; Summers, J. B.; Brooks, D. W.; Rubin, P.; Carter, G. W. The Discovery and Development of Zileuton: An Orally Active 5-Lipoxygenase Inhibitor Int. J. Immunopharmacol. 1992, 14 (3) 505-510 10.1016/0192-0561(92)90182-K
157. Gilbert, N. C.; Bartlett, S. G.; Waight, M. T.; Neau, D. B.; Boeglin, W. E.; Brash, A. R.; Newcomer, M. E. The Structure of Human 5-Lipoxygenase Science 2011, 331 (6014) 217-219 10.1126/science.1197203
158. Gilbert, N. C.; Rui, Z.; Neau, D. B.; Waight, M. T.; Bartlett, S. G.; Boeglin, W. E.; Brash, A. R.; Newcomer, M. E. Conversion of Human 5-Lipoxygenase to a 15-Lipoxygenase by a Point Mutation to Mimic Phosphorylation at Serine-663 FASEB J. 2012, 26 (8) 3222-3229 10.1096/fj.12-205286
159. Wang, J. L.; Limburg, D.; Graneto, M. J.; Springer, J.; Hamper, J. R. B.; Liao, S.; Pawlitz, J. L.; Kurumbail, R. G.; Maziasz, T.; Talley, J. J.; Kiefer, J. R.; Carter, J. The Novel Benzopyran Class of Selective Cyclooxygenase-2 Inhibitors. Part 2: The Second Clinical Candidate Having a Shorter and Favorable Human Half-Life Bioorg. Med. Chem. Lett. 2010, 20 (23) 7159-7163 10.1016/j.bmcl.2010.07.054
160. Vecchio, A. J.; Orlando, B. J.; Nandagiri, R.; Malkowski, M. G. Investigating Substrate Promiscuity in Cyclooxygenase-2: The Role of Arg-120 and Residues Lining the Hydrophobic Groove J. Biol. Chem. 2012, 287 (29) 24619-24630 10.1074/jbc.M112.372243
161. Sime, M.; Allan, A. C.; Chapman, P.; Fieldhouse, C.; Giblin, G. M. P.; Healy, M. P.; Lambert, M. H.; Leesnitzer, L. M.; Lewis, A.; Merrihew, R. V.; Rutter, R. A.; Sasse, R.; Shearer, B. G.; Willson, T. M.; Wilson, T. M.; Xu, R. X.; Virley, D. J. Discovery of GSK1997132B a Novel Centrally Penetrant Benzimidazole PPARγ Partial Agonist Bioorg. Med. Chem. Lett. 2011, 21 (18) 5568-5572 10.1016/j.bmcl.2011.06.088
162. Liberato, M. V.; Nascimento, A. S.; Ayers, S. D.; Lin, J. Z.; Cvoro, A.; Silveira, R. L.; Martínez, L.; Souza, P. C. T.; Saidemberg, D.; Deng, T.; Amato, A. A.; Togashi, M.; Hsueh, W. A.; Phillips, K.; Palma, M. S.; Neves, F. A. R.; Skaf, M. S.; Webb, P.; Polikarpov, I. Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists PLoS One 2012, 7 (5) e36297 10.1371/journal.pone.0036297
163. Lemurell, M.; Ulander, J.; Winiwarter, S.; Dahlén, A.; Davidsson, Ö.; Emtenäs, H.; Broddefalk, J.; Swanson, M.; Hovdal, D.; Plowright, A. T.; Pettersen, A.; Rydén-Landergren, M.; Barlind, J.; Llinas, A.; Herslöf, M.; Drmota, T.; Sigfridsson, K.; Moses, S.; Whatling, C. Discovery of AZD6642, an Inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the Treatment of Inflammatory Diseases J. Med. Chem. 2015, 58 (2) 897-911 10.1021/jm501531v
164. Liu, J.-Y.; Park, S.-H.; Morisseau, C.; Hwang, S. H.; Hammock, B. D.; Weiss, R. H. Sorafenib Has Soluble Epoxide Hydrolase Inhibitory Activity, Which Contributes to Its Effect Profile in Vivo Mol. Cancer Ther. 2009, 8 (8) 2193-2203 10.1158/1535-7163.MCT-09-0119
165. Wermuth, C. G. Selective Optimization of Side Activities: The SOSA Approach Drug Discovery Today 2006, 11 (3-4) 160-164 10.1016/S1359-6446(05)03686-X
166. Merk, D. Chances and Challenges of Retinoid X Receptor Gamma Targeting for Regenerative Multiple Sclerosis Treatment Future Med. Chem. 2015, 7 (18) 2411-2413 10.4155/fmc.15.163
167. Peters, J.-U. Polypharmacology-Foe or Friend? J. Med. Chem. 2013, 56 (22) 8955-8971 10.1021/jm400856t
168. Koeberle, A.; Werz, O. Multi-Target Approach for Natural Products in Inflammation Drug Discovery Today 2014, 19 (12) 1871-1882 10.1016/j.drudis.2014.08.006
169. Merk, D.; Lamers, C.; Ahmad, K.; Gomez, R. C.; Schneider, G.; Steinhilber, D.; Schubert-zsilavecz, M. Extending the Structure-Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist J. Med. Chem. 2014, 57 (19) 8035-8055 10.1021/jm500937v
170. Christiansen, E.; Hansen, S. V. F.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne, M. A.; Ulven, T. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes ACS Med. Chem. Lett. 2013, 4 (5) 441-445 10.1021/ml4000673
171. Blobaum, A. L.; Marnett, L. J. Molecular Determinants for the Selective Inhibition of Cyclooxygenase-2 by Lumiracoxib J. Biol. Chem. 2007, 282 (22) 16379-16390 10.1074/jbc.M609883200
172. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-Pyrazol-1-Yl]benze Nesulfonamide (SC-58635, Celecoxib) J. Med. Chem. 1997, 40 (9) 1347-1365 10.1021/jm960803q
173. Sierra, M. L.; Beneton, V.; Boullay, A.-B.; Boyer, T.; Brewster, A. G.; Donche, F.; Forest, M.-C.; Fouchet, M.-H.; Gellibert, F. J.; Grillot, D. A.; Lambert, M. H.; Laroze, A.; Le Grumelec, C.; Linget, J. M.; Montana, V. G.; Nguyen, V.-L.; Nicodème, E.; Patel, V.; Penfornis, A.; Pineau, O.; Pohin, D.; Potvain, F.; Poulain, G.; Ruault, C. B.; Saunders, M.; Toum, J.; Xu, H. E.; Xu, R. X.; Pianetti, P. M. Substituted 2-[(4-Aminomethyl)phenoxy]-2-Methylpropionic Acid PPARalpha Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents J. Med. Chem. 2007, 50 (4) 685-695 10.1021/jm058056x
174. Laufer, S. Discovery and Development of ML3000 Inflammopharmacology 2001, 9 (1-2) 101-112 10.1163/156856001300248371
175. Koeberle, A.; Siemoneit, U.; Bühring, U.; Northoff, H.; Laufer, S.; Albrecht, W.; Werz, O. Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 J. Pharmacol. Exp. Ther. 2008, 326 (3) 975-982 10.1124/jpet.108.139444
176. Fischer, L.; Hornig, M.; Pergola, C.; Meindl, N.; Franke, L.; Tanrikulu, Y.; Dodt, G.; Schneider, G.; Steinhilber, D.; Werz, O. The Molecular Mechanism of the Inhibition by Licofelone of the Biosynthesis of 5-Lipoxygenase Products Br. J. Pharmacol. 2007, 152 (4) 471-480 10.1038/sj.bjp.0707416
177. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48 (21) 6523-6543 10.1021/jm058225d
178. Blöcher, R.; Lamers, C.; Wittmann, S. K.; Merk, D.; Hartmann, M.; Weizel, L.; Diehl, O.; Brüggerhoff, A.; Boß, M.; Kaiser, A.; Schader, T.; Göbel, T.; Grundmann, M.; Angioni, C.; Heering, J.; Geisslinger, G.; Wurglics, M.; Kostenis, E.; Brüne, B.; Steinhilber, D.; Schubert-Zsilavecz, M.; Kahnt, A. S.; Proschak, E. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/peroxisome Proliferator-Activated Receptor γ Modulators J. Med. Chem. 2016, 59 (1) 61-81 10.1021/acs.jmedchem.5b01239
179. Moser, D.; Wisniewska, J. M.; Hahn, S.; Achenbach, J.; Buscató, E.; Klingler, F.-M.; Hofmann, B.; Steinhilber, D.; Proschak, E. Dual-Target Virtual Screening by Pharmacophore Elucidation and Molecular Shape Filtering ACS Med. Chem. Lett. 2012, 3 (2) 155-158 10.1021/ml200286e
180. Achenbach, J.; Klingler, F. M.; Blöcher, R.; Moser, D.; Häfner, A. K.; Rödl, C. B.; Kretschmer, S.; Krüger, B.; Löhr, F.; Stark, H.; Hofmann, B.; Steinhilber, D.; Proschak, E. Exploring the Chemical Space of Multitarget Ligands Using Aligned Self-Organizing Maps ACS Med. Chem. Lett. 2013, 4 (12) 1169-1172 10.1021/ml4002562
181. Morphy, R.; Rankovic, Z. The Physicochemical Challenges of Designing Multiple Ligands J. Med. Chem. 2006, 49 (16) 4961-4970 10.1021/jm0603015
182. Böcker, A.; Bonneau, P. R.; Hucke, O.; Jakalian, A.; Edwards, P. J. Development of Specific "drug-like Property" rules for Carboxylate-Containing Oral Drug Candidates ChemMedChem 2010, 5 (12) 2102-2113 10.1002/cmdc.201000355
183. Charifson, P. S.; Walters, W. P. Acidic and Basic Drugs in Medicinal Chemistry: A Perspective J. Med. Chem. 2014, 57 (23) 9701-9717 10.1021/jm501000a
184. Meanwell, N. A. Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety Chem. Res. Toxicol. 2011, 24 (9) 1420-1456 10.1021/tx200211v
185. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb J. Med. Chem. 2008, 51 (4) 817-834 10.1021/jm701122q
186. Gleeson, P.; Bravi, G.; Modi, S.; Lowe, D. ADMET Rules of Thumb II: A Comparison of the Effects of Common Substituents on a Range of ADMET Parameters Bioorg. Med. Chem. 2009, 17 (16) 5906-5919 10.1016/j.bmc.2009.07.002
187. Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET; Smith, D. A., Ed.; RSC Drug Discovery; Royal Society of Chemistry: Cambridge, U.K., 2010.
188. Lemke, T. L.; Roche, V. F.; Zito, S. W. Review of Organic Functional Groups: Introduction to Medicinal Organic Chemistry; Wolters Kluwer/Lippincott Williams & Wilkins Health: Philadelphia, PA, 2012.
189. Meanwell, N. A. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space Chem. Res. Toxicol. 2016, 29 (4) 564-616 10.1021/acs.chemrestox.6b00043
190. Manallack, D. T.; Prankerd, R. J.; Yuriev, E.; Oprea, T. I.; Chalmers, D. K. The Significance of Acid/base Properties in Drug Discovery Chem. Soc. Rev. 2013, 42 (2) 485-496 10.1039/C2CS35348B
191. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings Adv. Drug Delivery Rev. 1997, 23 (1-3) 3-25 10.1016/S0169-409X(96)00423-1
192. Varma, M. V. S.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-Kattan, A.; Troutman, M. D. Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination J. Med. Chem. 2010, 53 (3) 1098-1108 10.1021/jm901371v
193. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural Basis of the Drug-Binding Specificity of Human Serum Albumin J. Mol. Biol. 2005, 353 (1) 38-52 10.1016/j.jmb.2005.07.075
194. Alves, A. C.; Ribeiro, D.; Nunes, C.; Reis, S. Biophysics in Cancer: The Relevance of Drug-Membrane Interaction Studies Biochim. Biophys. Acta, Biomembr. 2016, 1858 (9) 2231-2244 10.1016/j.bbamem.2016.06.025
195. Tsuchiya, H. Membrane Interactions of Phytochemicals as Their Molecular Mechanism Applicable to the Discovery of Drug Leads from Plants Molecules 2015, 20 (10) 18923-18966 10.3390/molecules201018923
196. Deleu, M.; Crowet, J.-M.; Nasir, M. N.; Lins, L. Complementary Biophysical Tools to Investigate Lipid Specificity in the Interaction between Bioactive Molecules and the Plasma Membrane: A Review Biochim. Biophys. Acta, Biomembr. 2014, 1838 (12) 3171-3190 10.1016/j.bbamem.2014.08.023
197. Maeda, K. Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 as Important Regulators of the Pharmacokinetics of Substrate Drugs Biol. Pharm. Bull. 2015, 38 (2) 155-168 10.1248/bpb.b14-00767
198. Shitara, Y.; Maeda, K.; Ikejiri, K.; Yoshida, K.; Horie, T.; Sugiyama, Y. Clinical Significance of Organic Anion Transporting Polypeptides (OATPs) in Drug Disposition: Their Roles in Hepatic Clearance and Intestinal Absorption Biopharm. Drug Dispos. 2013, 34 (1) 45-78 10.1002/bdd.1823
199. Wolkoff, A. W. Organic Anion Uptake by Hepatocytes Compr. Physiol. 2014, 4 (4) 1715-1735 10.1002/cphy.c140023
200. Gao, Y.; Shao, J.; Jiang, Z.; Chen, J.; Gu, S.; Yu, S.; Zheng, K.; Jia, L. Drug Enterohepatic Circulation and Disposition: Constituents of Systems Pharmacokinetics Drug Discovery Today 2014, 19 (3) 326-340 10.1016/j.drudis.2013.11.020
201. Varma, M. V.; Feng, B.; Obach, R. S.; Troutman, M. D.; Chupka, J.; Miller, H. R.; El-Kattan, A. Physicochemical Determinants of Human Renal Clearance J. Med. Chem. 2009, 52 (15) 4844-4852 10.1021/jm900403j
202. Olsen, L.; Oostenbrink, C.; Jørgensen, F. S. Prediction of Cytochrome P450 Mediated Metabolism Adv. Drug Delivery Rev. 2015, 86, 61-71 10.1016/j.addr.2015.04.020
203. Kirchmair, J.; Göller, A. H.; Lang, D.; Kunze, J.; Testa, B.; Wilson, I. D.; Glen, R. C.; Schneider, G. Predicting Drug Metabolism: Experiment And/or Computation? Nat. Rev. Drug Discovery 2015, 14 (6) 387-404 10.1038/nrd4581
204. Trunzer, M.; Faller, B.; Zimmerlin, A. Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases Using MetaSite and LC-MS/MS Validation J. Med. Chem. 2009, 52 (2) 329-335 10.1021/jm8008663
205. Zelesky, V.; Schneider, R.; Janiszewski, J.; Zamora, I.; Ferguson, J.; Troutman, M. Software Automation Tools for Increased Throughput Metabolic Soft-Spot Identification in Early Drug Discovery Bioanalysis 2013, 5 (10) 1165-1179 10.4155/bio.13.89
206. Braga, R. C.; Andrade, C. H. QSAR and QM/MM Approaches Applied to Drug Metabolism Prediction Mini-Rev. Med. Chem. 2012, 12 (6) 573-582 10.2174/138955712800493807
207. Shin, Y. G.; Le, H.; Khojasteh, C.; Hop, C. E. C. A. Comparison of Metabolic Soft Spot Predictions of CYP3A4, CYP2C9 and CYP2D6 Substrates Using MetaSite and StarDrop Comb. Chem. High Throughput Screening 2011, 14 (9) 811-823 10.2174/138620711796957170
208. Walsh, D. A.; Moran, H. W.; Shamblee, D. A.; Uwaydah, I. M.; Welstead, W. J.; Sancilio, L. F.; Dannenburg, W. N. Antiinflammatory Agents. 3. Synthesis and Pharmacological Evaluation of 2-Amino-3-Benzoylphenylacetic Acid and Analogues J. Med. Chem. 1984, 27 (11) 1379-1388 10.1021/jm00377a001
209. Walsh, D. A.; Moran, H. W.; Shamblee, D. A.; Welstead, W. J.; Nolan, J. C.; Sancilio, L. F.; Graff, G. Antiinflammatory Agents. 4. Syntheses and Biological Evaluation of Potential Prodrugs of 2-Amino-3-Benzoylbenzeneacetic Acid and 2-Amino-3-(4-Chlorobenzoyl)benzeneacetic Acid J. Med. Chem. 1990, 33 (8) 2296-2304 10.1021/jm00170a039
210. Walters, T.; Raizman, M.; Ernest, P.; Gayton, J.; Lehmann, R. In Vivo Pharmacokinetics and in Vitro Pharmacodynamics of Nepafenac, Amfenac, Ketorolac, and Bromfenac J. Cataract Refractive Surg. 2007, 33 (9) 1539-1545 10.1016/j.jcrs.2007.05.015
211. Gamache, D. A.; Graff, G.; Brady, M. T.; Spellman, J. M.; Yanni, J. M. Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy Inflammation 2000, 24 (4) 357-370 10.1023/A:1007049015148
212. Talley, J. J.; Bertenshaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-Methyl-3-Phenylisoxazol-4-Yl)-Phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration J. Med. Chem. 2000, 43 (9) 1661-1663 10.1021/jm000069h
213. Leeson, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6 (11) 881-890 10.1038/nrd2445
214. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can We Rationally Design Promiscuous Drugs? Curr. Opin. Struct. Biol. 2006, 16 (1) 127-136 10.1016/j.sbi.2006.01.013
215. Peters, J.-U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds ChemMedChem 2009, 4 (4) 680-686 10.1002/cmdc.200800411
216. Reker, D.; Perna, A. M.; Rodrigues, T.; Schneider, P.; Reutlinger, M.; Mönch, B.; Koeberle, A.; Lamers, C.; Gabler, M.; Steinmetz, H.; Müller, R.; Schubert-Zsilavecz, M.; Werz, O.; Schneider, G. Revealing the Macromolecular Targets of Complex Natural Products Nat. Chem. 2014, 6 (12) 1072-1078 10.1038/nchem.2095
217. Rodrigues, T.; Reker, D.; Kunze, J.; Schneider, P.; Schneider, G. Revealing the Macromolecular Targets of Fragment-Like Natural Products Angew. Chem., Int. Ed. 2015, 54 (36) 10516-10520 10.1002/anie.201504241
218. Rayan, A.; Falah, M.; Raiyn, J.; Da'adoosh, B.; Kadan, S.; Zaid, H.; Goldblum, A. Indexing Molecules for Their hERG Liability Eur. J. Med. Chem. 2013, 65, 304-314 10.1016/j.ejmech.2013.04.059
219. Murphy, R. C.; Hammarström, S.; Samuelsson, B.; Leukotriene, C. A Slow-Reacting Substance from Murine Mastocytoma Cells Proc. Natl. Acad. Sci. U. S. A. 1979, 76 (9) 4275-4279 10.1073/pnas.76.9.4275
220. Jones, D. G.; Kay, A. B. Inhibition of Eosinophil Chemotaxis by the Antagonist of Slow Reacting Substance of Anaphylaxis - Compound FPL 55712 J. Pharm. Pharmacol. 1974, 26 (11) 917-918 10.1111/j.2042-7158.1974.tb09208.x
221. Augstein, J.; Farmer, J. B.; Lee, T. B.; Sheard, P.; Tattersall, M. L. Selective Inhibitor of Slow Reacting Substance of Anaphylaxis Nat. New Biol. 1973, 245 (146) 215-217 10.1038/newbio245215a0
222. Dahlén, S.-E. Leukotriene Receptors Clin. Rev. Allergy Immunol. 1999, 17 (1-2) 179-191 10.1007/BF02737603
223. Bernstein, P. R. Chemistry and Structure-Activity Relationships of Leukotriene Receptor Antagonists Am. J. Respir. Crit. Care Med. 1998, 157 (6) S220-S226 10.1164/ajrccm.157.6.mar-3
224. Brown, F. J.; Bernstein, P. R.; Cronk, L. A.; Dosset, D. L.; Hebbel, K. C.; Maduskuie, T. P.; Shapiro, H. S.; Vacek, E. P.; Yee, Y. K. Hydroxyacetophenone-Derived Antagonists of the Peptidoleukotrienes J. Med. Chem. 1989, 32 (4) 807-826 10.1021/jm00124a014
225. Nakai, H.; Konno, M.; Kosuge, S.; Sakuyama, S.; Toda, M.; Arai, Y.; Obata, T.; Katsube, N.; Miyamoto, T. New Potent Antagonists of Leukotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships J. Med. Chem. 1988, 31 (1) 84-91 10.1021/jm00396a013
226. Brocks, D. R.; Upward, J.; Davy, M.; Howland, K.; Compton, C.; McHugh, C.; Dennis, M. J. Evening Dosing Is Associated with Higher Plasma Concentrations of Pranlukast, a Leukotriene Receptor Antagonist, in Healthy Male Volunteers Br. J. Clin. Pharmacol. 1997, 44 (3) 289-291 10.1046/j.1365-2125.1997.00650.x
227. Sarau, H. M.; Ames, R. S.; Chambers, J.; Ellis, C.; Elshourbagy, N.; Foley, J. J.; Schmidt, D. B.; Muccitelli, R. M.; Jenkins, O.; Murdock, P. R.; Herrity, N. C.; Halsey, W.; Sathe, G.; Muir, A. I.; Nuthulaganti, P.; Dytko, G. M.; Buckley, P. T.; Wilson, S.; Bergsma, D. J.; Hay, D. W. P. Identification, Molecular Cloning, Expression, and Characterization of a Cysteinyl Leukotriene Receptor Mol. Pharmacol. 1999, 56 (3) 657-663
228. Lynch, K. R.; O'Neill, G. P.; Liu, Q.; Im, D. S.; Sawyer, N.; Metters, K. M.; Coulombe, N.; Abramovitz, M.; Figueroa, D. J.; Zeng, Z.; Connolly, B. M.; Bai, C.; Austin, C. P.; Chateauneuf, A.; Stocco, R.; Greig, G. M.; Kargman, S.; Hooks, S. B.; Hosfield, E.; Williams, D. L.; Ford-Hutchinson, A. W.; Caskey, C. T.; Evans, J. F. Characterization of the Human Cysteinyl Leukotriene CysLT1 Receptor Nature 1999, 399 (6738) 789-793 10.1038/21658
229. Obata, T.; Okada, Y.; Motoishi, M.; Nakagawa, N.; Terawaki, T.; Aishita, H. In Vitro Antagonism of ONO-1078, a Newly Developed Anti-Asthma Agent, against Peptide Leukotrienes in Isolated Guinea Pig Tissues Jpn. J. Pharmacol. 1992, 60 (3) 227-237 10.1254/jjp.60.227
230. Barnes, N. C.; Pujet, J. C. Pranlukast, a Novel Leukotriene Receptor Antagonist: Results of the First European, Placebo Controlled, Multicentre Clinical Study in Asthma Thorax 1997, 52 (6) 523-527 10.1136/thx.52.6.523
231. Bernstein, P. R.; Snyder, D. W.; Adams, E. J.; Krell, R. D.; Vacek, E. P.; Willard, A. K. Chemically Stable Homocinnamyl Analogs of the Leukotrienes: Synthesis and Preliminary Biological Evaluation J. Med. Chem. 1986, 29 (12) 2477-2483 10.1021/jm00162a010
232. Bernstein, P. R.; Vacek, E. P.; Adams, E. J.; Snyder, D. W.; Krell, R. D. Synthesis and Pharmacological Characterization of a Series of Leukotriene Analogs with Antagonist and Agonist Activities J. Med. Chem. 1988, 31 (3) 692-696 10.1021/jm00398a033
233. 4 Receptor Antagonist Can. J. Physiol. Pharmacol. 1995, 73 (2) 191-201 10.1139/y95-028
234. Nothacker, H.-P.; Wang, Z.; Zhu, Y.; Reinscheid, R. K.; Lin, S. H. S.; Civelli, O. Molecular Cloning and Characterization of a Second Human Cysteinyl Leukotriene Receptor: Discovery of a Subtype Selective Agonist Mol. Pharmacol. 2000, 58 (6) 1601-1608
235. Labelle, M.; Prasit, P.; Belley, M.; Blouin, M.; Champion, E.; Charette, L.; DeLuca, J. G.; Dufresne, C.; Frenette, R.; Gauthier, J. Y.; Grimm, E.; Grossman, S. J.; Guay, D.; Herold, E. G.; Jones, T. R.; Lau, C. K.; Leblanc, Y.; Léger, S.; Lord, A.; McAuliffe, M.; McFarlane, C.; Masson, P.; Metters, K. M.; Ouimet, N.; Patrick, D. H.; Perrier, H.; Pickett, C. B.; Piechuta, H.; Roy, P.; Williams, H.; Wang, Z.; Xiang, Y. B.; Zamboni, R. J.; Ford-Hutchinson, A. W.; Young, R. N. The Discovery of a New Structural Class of Potent Orally Active Leukotriene D4 Antagonists Bioorg. Med. Chem. Lett. 1992, 2 (9) 1141-1146 10.1016/S0960-894X(00)80635-6
236. Labelle, M.; Belley, M.; Gareau, Y.; Gauthier, J. Y.; Guay, D.; Gordon, R.; Grossman, S. G.; Jones, T. R.; Leblanc, Y.; McAuliffe, M.; McFarlane, C.; Masson, P.; Metters, K. M.; Ouimet, N.; Patrick, D. H.; Piechuta, H.; Rochette, C.; Sawyer, N.; Xiang, Y. B.; Pickett, C. B.; Ford-Hutchinson, A. W.; Zamboni, R. J.; Young, R. N. Discovery of MK-0476, a Potent and Orally Active Leukotriene D4 Receptor Antagonist Devoid of Peroxisomal Enxyme Induction Bioorg. Med. Chem. Lett. 1995, 5 (3) 283-288 10.1016/0960-894X(95)00023-M
237. Capra, V.; Carnini, C.; Accomazzo, M. R.; Di Gennaro, A.; Fiumicelli, M.; Borroni, E.; Brivio, I.; Buccellati, C.; Mangano, P.; Carnevali, S.; Rovati, G.; Sala, A. Autocrine Activity of Cysteinyl Leukotrienes in Human Vascular Endothelial Cells: Signaling through the CysLT2 Receptor Prostaglandins Other Lipid Mediators 2015, 120, 115-125 10.1016/j.prostaglandins.2015.03.007
238. Cheng, H.; Leff, J. A.; Amin, R.; Gertz, B. J.; De Smet, M.; Noonan, N.; Rogers, J. D.; Malbecq, W.; Meisner, D.; Somers, G. Pharmacokinetics, Bioavailability, and Safety of Montelukast Sodium (MK-0476) in Healthy Males and Females Pharm. Res. 1996, 13 (3) 445-448 10.1023/A:1016056912698
239. Reiss, T. F.; Altman, L. C.; Chervinsky, P.; Bewtra, A.; Stricker, W. E.; Noonana, G. P.; Kundu, S.; Zhang, J. Effects of Montelukast (MK-0476), a New Potent Cysteinyl Leukotriene (LTD4) Receptor Antagonist, in Patients with Chronic Asthma J. Allergy Clin. Immunol. 1996, 98 (3) 528-534 10.1016/S0091-6749(96)70086-6
240. Brown, F. J.; Yee, Y. K.; Cronk, L. A.; Hebbel, K. C.; Krell, R. D.; Snyder, D. W. Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles J. Med. Chem. 1990, 33 (6) 1771-1781 10.1021/jm00168a036
241. Yee, Y. K.; Bernstein, P. R.; Adams, E. J.; Brown, F. J.; Cronk, L. A.; Hebbel, K. C.; Vacek, E. P.; Krell, R. D.; Snyder, D. W. A Novel Series of Selective Leukotriene Antagonists: Exploration and Optimization of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles J. Med. Chem. 1990, 33 (9) 2437-2451 10.1021/jm00171a018
242. Snyder, D. W.; Giles, R. E.; Keith, R. A.; Yee, Y. K.; Krell, R. D. In Vitro Pharmacology of ICI 198,615: A Novel, Potent and Selective Peptide Leukotriene Antagonist J. Pharmacol. Exp. Ther. 1987, 243 (2) 548-556
243. Shukla, S. J.; Sakamuru, S.; Huang, R.; Moeller, T. A.; Shinn, P.; VanLeer, D.; Auld, D. S.; Austin, C. P.; Xia, M. Identification of Clinically Used Drugs That Activate Pregnane X Receptors Drug Metab. Dispos. 2011, 39 (1) 151-159 10.1124/dmd.110.035105